Author Archives: admin
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has […]
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical […]
Merit Medical Launches the Ventrax™ Delivery System
Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing […]
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200 participants—marking two-thirds of its target enrollment. This milestone positions the study as one of the largest remote […]
Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City
BioUtah member, Denali Therapeutics, yesterday celebrated the grand opening of its new state-of-the-art manufacturing facility in Salt Lake City. Denali is using deep scientific and drug development expertise to discover and deliver effective biologic therapeutics to the brain. Co-founder and CEO, Ryan Watts, addressed the crowd who gathered to share the milestone with colleagues, public […]
bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO
Marcy l’Étoile, France, March 18th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat […]
Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research
Fully Sponsored BioLabs Lab Space to Support Halia’s Next Phase of Development LEHI, Utah, Feb. 25, 2025 /PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for chronic inflammation and obesity-related diseases, announced today that it has been awarded the Novo Nordisk Golden Ticket. This prestigious award provides Halia with a fully sponsored […]
Kelvyn Cullimore Joins KSL Radio’s Inside Sources
SALT LAKE CITY, January 23, 2025—Today BioUtah president and CEO Kelvyn Cullimore joined KSL Radio’s Inside Sources to discuss the life sciences industry in the State of Utah. Hosted by Maura Carabello and Adam Gardiner, Inside Sources daily broadcast covers political issues affecting Utah. Today, Carabello and Gardiner interviewed Cullimore to spotlight Utah’s life sciences industry and […]
ARUP Offers New Assay To Detect Influenza A (H5) Virus
SALT LAKE CITY, January 3, 2025—ARUP Laboratories today launched a new assay for the detection and subtyping of influenza A (H5) virus. This test will aid in the evaluation of individuals who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu. In early 2024, an outbreak […]
NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD
VALENCIA, Calif. – Dec. 3, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced the creation of a Medical Radioisotopes Advisory Board. This panel of internationally recognized leaders in nuclear medicine will provide strategic guidance to Nusano, ensuring its product development aligns with emerging trends and with the needs of cancer […]
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.’s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India. In support of the “Make […]
Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)
LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today promising topline data resulting in the advancement to the second stage of its Phase 2 clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk […]
